Kivu Bioscience, a biotechnology company advancing next-generation antibody-drug conjugates (ADCs) for difficult-to-treat cancers, today announced the appointment of Sophia Randolph, M.D., Ph.D., as Chief Medical Officer. As a medical oncologist, Dr. Randolph brings over 20 years of experience in oncology drug development advancing novel therapeutics from preclinical through late-stage settings.
